Key Financial Figures - Standalone (INR Lacs)
Quarter Ended June 30, 2026:
- Total Income: ₹2,224.73
- Total Expenses: ₹2,039.65
- Profit Before Tax: ₹185.08
- Tax Expense: ₹47.65 (Current Tax: ₹33.00, Deferred Tax: ₹14.65)
- Profit for the Period: ₹137.43
- Other Comprehensive Income (net of tax): ₹21.79
- Total Comprehensive Income: ₹159.22
- Basic EPS: ₹0.93
- Diluted EPS: ₹0.93
Comparative Figures - Quarter Ended June 30, 2025:
- Total Income: ₹1,735.44
- Profit for the Period: ₹58.45
- Basic EPS: ₹0.39
Comparative Figures - Quarter Ended March 31, 2026:
- Total Income: ₹7,480.92
- Profit for the Period: ₹198.68
- Basic EPS: ₹1.34
Key Financial Figures - Consolidated (INR Lacs)
Quarter Ended June 30, 2026:
- Revenue from Operations: ₹2,193.82
- Other Income: ₹10.54
- Total Income: ₹2,204.37
- Total Expenses: ₹2,106.19
- Profit Before Tax: ₹98.17
- Tax Expense: ₹47.65 (Current Tax: ₹33.00, Deferred Tax: ₹14.65)
- Profit for the Period: ₹50.52
- Total Comprehensive Income: ₹72.31
- Basic EPS: ₹0.34
- Diluted EPS: ₹0.34
Entities Consolidated: Kalichem Private Limited (Wholly-Owned Subsidiary)
Corporate Actions
- On 15th May 2026, the Company granted 1,07,700 Employee Stock Options to eligible employees under the Chemcrux Enterprises Employee Stock Option Scheme 2025 (ESOP 2025 Scheme) at an exercise price of ₹10 per share with a vesting period of one year.
- The Company has estimated the fair value of these options on the grant date and recognized proportionate employee benefit expense in the Statement of Profit and Loss for the quarter.
Regulatory and Accounting Context
- Financial results prepared in accordance with Indian Accounting Standards (Ind AS)
- Reviewed by Audit Committee and approved by Board of Directors on 04th August 2026
- The Company is primarily engaged in manufacturing and processing of Bulk Drug Intermediates (single operating segment)
- Government of India implemented New Labour Codes effective 21 November 2025 - employee benefit expenses accounted accordingly with no material impact on financial results
- Diluted EPS calculated considering effect of Employee Stock Options with no material effect
Meeting Details
- Board Meeting held on 04th August 2026
- Meeting commenced at 05:00 PM and concluded at 07:20 PM
- Results approved by the Board as recommended by the Audit Committee
Auditor Review
- Independent auditor's limited review report provided by Naresh & Co., Chartered Accountants
- Review conducted in accordance with Standard on Review Engagement (SRE) 2410
- No material misstatement identified in the financial results